2026 Q2 -tulosraportti
Vain PDF
8 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sitten · MuokattuNow that I have informed how medical cannabis should be handled, and Muldyr made me go into detail, you have all received the same knowledge about how expensive and difficult it is when a pharmacy wants to stock Weeco Astrum10/10 (as well as other cannabis products). The pharmacies that stock Weeco Astrum 10/10 are where doctors prescribe Weeco Astrum 10/10. It is only because many people buy Weeco Astrum 10/10 that they have the oil in stock. If only a few prescriptions were issued, Weeco Astrum 10/10 would be an order item. That's the only reason I know that Stenocare has sold well in Germany in Q2 because many pharmacies have had the oil in stock since May 13th, when I started performing stock status checks. Based on this knowledge, can you then understand that in this case it is secondary knowledge how many bottles they sell per pharmacy? Here is the most important knowledge: do they sell anything or not. Based on the above, we can see that they do, and they have done so since Weeco Pharma took over the task from ADREX Pharma. When I see that it's sold out, it means that the stock cannot keep up in the areas where it's sold out, and when it's quickly refilled within 24 hours, it means they expect additional sales within a short time. In this area, so many prescriptions are being written that the stock cannot keep up. This is the reason why I continue to perform stock status checks, and I will continue until it no longer makes sense. It is a rarity that one can follow in real time, but we can here, so therefore it would be more than foolish to stop now.Right now nothing is happening in France because parliament is on holiday and will return again in September. What we are waiting for now is for President Macron to sign the decree, so they can move forward with their roadmap for medical cannabis.- ·1 päivä sittenThis evening, all Canngo's pharmacies have received Weeco Astrum 10/10 back in stock. It was one pharmacy that reported being sold out yesterday afternoon.I'm just reminding you that in a post you yourself very clearly wrote that one cannot use these statements to estimate what the sales are. And yet, directly against your own advice, that is exactly what you are doing and have always done every day, constantly and all the time. So there is a reason why all your predictions and estimates have failed 100%, and that on all points. If you had then learned just a little from your mistakes and adjusted the method just a little, then I might have been able to understand you. But you don't. You relentlessly continue to use a method that has proven unusable and consequently, one cannot use your posts for anything at all.
- ·2 päivää sittenTo those of you who want the same knowledge I have acquired, about how medical cannabis should be handled when a batch of the above arrives at the German airport and subsequently. First, I want to inform you that it is very complicated, as I have written many times before. So, I will not go into detail. Every time I encountered this and that which I didn't understand, I investigated it as best I could. First, a batch is flown to Germany. At the airport, the batch must be released before it can proceed to its destination in Germany. This happens when customs officers check that everything is as it should be. Flower medicine is said to be a more extensive process than oils and extracts. Once a batch is released by customs, it must proceed to the warehouse that a distributor has for this purpose. Before the distributors, in this case Weeco Pharma, can distribute the bottles of oil to the pharmacies that have placed orders for them, Weeco Pharma must register this batch according to the applicable legislation and send this to the relevant authority. This happens as follows. The batch must be tested, and a batch-specific analysis certificate must be available, proving that the oil complies with the requirements of the German drug monograph; this is a complicated process, and the batch can only proceed once the authorities have given the green light. Just a very important detail: No distributor may order more medical cannabis than they know there are prescriptions for. They are therefore not allowed to order more cannabis medicine based on their hunches or forecasts, because they believe there will be a boom. That is why we see signs of bottlenecks across the board, because even though they could probably figure out that this boom would come, Weeco Pharma could not buy extra oil as a precaution. Now the oil has arrived at the pharmacies that ordered it. The same rule applies to pharmacies; they may not order more cannabis medicine than they can document there are prescriptions for. When the oil arrives at the pharmacy, the pharmacy must perform a laboratory test to confirm the product's identity, that the content actually matches the label. Documentation: The result of this test is entered into the pharmacy's internal logbooks. As soon as the pharmacy has completed its own internal incoming inspection and documented it, they may sell the oil immediately to patients with a valid prescription. Germany is known for having the most regulating and strict legislation for cannabis medicine. That was broadly how it works in Germany. It is also why I cannot immediately ascertain whether a batch has been released or whether the few pharmacies that have the oil in stock again have bought it internally. (Which pharmacies also need to be approved for) I hope that the above has given you a better understanding of why we are currently experiencing signs of drought in Germany right now.
Denmark actually has a very strict and specific set of rules in this area. It has therefore been difficult to build a broad product portfolio, because both companies and specific products must meet Danish legal requirements before they can be included in the scheme. Perhaps one might also wonder why Astrum is not (yet) available in DK. In Denmark, the doctor must simultaneously take full responsibility for the prescription, including assessing dosage, effect, and risk of side effects themselves. This is, among other things, one of the issues that can make doctors reluctant to prescribe medical cannabis. And aren't you confusing different product categories with magistral preparation? Here, the medicine is prepared at the pharmacy according to the doctor's instructions for the specific patient. So it's a bit more extensive than "scan the barcode and dispense". In fact, a lot of cannabis comes this way - also in Germany. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/ordningen-med-medicinsk-cannabis/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Vain PDF
8 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuNow that I have informed how medical cannabis should be handled, and Muldyr made me go into detail, you have all received the same knowledge about how expensive and difficult it is when a pharmacy wants to stock Weeco Astrum10/10 (as well as other cannabis products). The pharmacies that stock Weeco Astrum 10/10 are where doctors prescribe Weeco Astrum 10/10. It is only because many people buy Weeco Astrum 10/10 that they have the oil in stock. If only a few prescriptions were issued, Weeco Astrum 10/10 would be an order item. That's the only reason I know that Stenocare has sold well in Germany in Q2 because many pharmacies have had the oil in stock since May 13th, when I started performing stock status checks. Based on this knowledge, can you then understand that in this case it is secondary knowledge how many bottles they sell per pharmacy? Here is the most important knowledge: do they sell anything or not. Based on the above, we can see that they do, and they have done so since Weeco Pharma took over the task from ADREX Pharma. When I see that it's sold out, it means that the stock cannot keep up in the areas where it's sold out, and when it's quickly refilled within 24 hours, it means they expect additional sales within a short time. In this area, so many prescriptions are being written that the stock cannot keep up. This is the reason why I continue to perform stock status checks, and I will continue until it no longer makes sense. It is a rarity that one can follow in real time, but we can here, so therefore it would be more than foolish to stop now.Right now nothing is happening in France because parliament is on holiday and will return again in September. What we are waiting for now is for President Macron to sign the decree, so they can move forward with their roadmap for medical cannabis.
- ·1 päivä sittenThis evening, all Canngo's pharmacies have received Weeco Astrum 10/10 back in stock. It was one pharmacy that reported being sold out yesterday afternoon.I'm just reminding you that in a post you yourself very clearly wrote that one cannot use these statements to estimate what the sales are. And yet, directly against your own advice, that is exactly what you are doing and have always done every day, constantly and all the time. So there is a reason why all your predictions and estimates have failed 100%, and that on all points. If you had then learned just a little from your mistakes and adjusted the method just a little, then I might have been able to understand you. But you don't. You relentlessly continue to use a method that has proven unusable and consequently, one cannot use your posts for anything at all.
- ·2 päivää sittenTo those of you who want the same knowledge I have acquired, about how medical cannabis should be handled when a batch of the above arrives at the German airport and subsequently. First, I want to inform you that it is very complicated, as I have written many times before. So, I will not go into detail. Every time I encountered this and that which I didn't understand, I investigated it as best I could. First, a batch is flown to Germany. At the airport, the batch must be released before it can proceed to its destination in Germany. This happens when customs officers check that everything is as it should be. Flower medicine is said to be a more extensive process than oils and extracts. Once a batch is released by customs, it must proceed to the warehouse that a distributor has for this purpose. Before the distributors, in this case Weeco Pharma, can distribute the bottles of oil to the pharmacies that have placed orders for them, Weeco Pharma must register this batch according to the applicable legislation and send this to the relevant authority. This happens as follows. The batch must be tested, and a batch-specific analysis certificate must be available, proving that the oil complies with the requirements of the German drug monograph; this is a complicated process, and the batch can only proceed once the authorities have given the green light. Just a very important detail: No distributor may order more medical cannabis than they know there are prescriptions for. They are therefore not allowed to order more cannabis medicine based on their hunches or forecasts, because they believe there will be a boom. That is why we see signs of bottlenecks across the board, because even though they could probably figure out that this boom would come, Weeco Pharma could not buy extra oil as a precaution. Now the oil has arrived at the pharmacies that ordered it. The same rule applies to pharmacies; they may not order more cannabis medicine than they can document there are prescriptions for. When the oil arrives at the pharmacy, the pharmacy must perform a laboratory test to confirm the product's identity, that the content actually matches the label. Documentation: The result of this test is entered into the pharmacy's internal logbooks. As soon as the pharmacy has completed its own internal incoming inspection and documented it, they may sell the oil immediately to patients with a valid prescription. Germany is known for having the most regulating and strict legislation for cannabis medicine. That was broadly how it works in Germany. It is also why I cannot immediately ascertain whether a batch has been released or whether the few pharmacies that have the oil in stock again have bought it internally. (Which pharmacies also need to be approved for) I hope that the above has given you a better understanding of why we are currently experiencing signs of drought in Germany right now.Denmark actually has a very strict and specific set of rules in this area. It has therefore been difficult to build a broad product portfolio, because both companies and specific products must meet Danish legal requirements before they can be included in the scheme. Perhaps one might also wonder why Astrum is not (yet) available in DK. In Denmark, the doctor must simultaneously take full responsibility for the prescription, including assessing dosage, effect, and risk of side effects themselves. This is, among other things, one of the issues that can make doctors reluctant to prescribe medical cannabis. And aren't you confusing different product categories with magistral preparation? Here, the medicine is prepared at the pharmacy according to the doctor's instructions for the specific patient. So it's a bit more extensive than "scan the barcode and dispense". In fact, a lot of cannabis comes this way - also in Germany. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/ordningen-med-medicinsk-cannabis/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
2026 Q2 -tulosraportti
Vain PDF
8 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sitten · MuokattuNow that I have informed how medical cannabis should be handled, and Muldyr made me go into detail, you have all received the same knowledge about how expensive and difficult it is when a pharmacy wants to stock Weeco Astrum10/10 (as well as other cannabis products). The pharmacies that stock Weeco Astrum 10/10 are where doctors prescribe Weeco Astrum 10/10. It is only because many people buy Weeco Astrum 10/10 that they have the oil in stock. If only a few prescriptions were issued, Weeco Astrum 10/10 would be an order item. That's the only reason I know that Stenocare has sold well in Germany in Q2 because many pharmacies have had the oil in stock since May 13th, when I started performing stock status checks. Based on this knowledge, can you then understand that in this case it is secondary knowledge how many bottles they sell per pharmacy? Here is the most important knowledge: do they sell anything or not. Based on the above, we can see that they do, and they have done so since Weeco Pharma took over the task from ADREX Pharma. When I see that it's sold out, it means that the stock cannot keep up in the areas where it's sold out, and when it's quickly refilled within 24 hours, it means they expect additional sales within a short time. In this area, so many prescriptions are being written that the stock cannot keep up. This is the reason why I continue to perform stock status checks, and I will continue until it no longer makes sense. It is a rarity that one can follow in real time, but we can here, so therefore it would be more than foolish to stop now.Right now nothing is happening in France because parliament is on holiday and will return again in September. What we are waiting for now is for President Macron to sign the decree, so they can move forward with their roadmap for medical cannabis.
- ·1 päivä sittenThis evening, all Canngo's pharmacies have received Weeco Astrum 10/10 back in stock. It was one pharmacy that reported being sold out yesterday afternoon.I'm just reminding you that in a post you yourself very clearly wrote that one cannot use these statements to estimate what the sales are. And yet, directly against your own advice, that is exactly what you are doing and have always done every day, constantly and all the time. So there is a reason why all your predictions and estimates have failed 100%, and that on all points. If you had then learned just a little from your mistakes and adjusted the method just a little, then I might have been able to understand you. But you don't. You relentlessly continue to use a method that has proven unusable and consequently, one cannot use your posts for anything at all.
- ·2 päivää sittenTo those of you who want the same knowledge I have acquired, about how medical cannabis should be handled when a batch of the above arrives at the German airport and subsequently. First, I want to inform you that it is very complicated, as I have written many times before. So, I will not go into detail. Every time I encountered this and that which I didn't understand, I investigated it as best I could. First, a batch is flown to Germany. At the airport, the batch must be released before it can proceed to its destination in Germany. This happens when customs officers check that everything is as it should be. Flower medicine is said to be a more extensive process than oils and extracts. Once a batch is released by customs, it must proceed to the warehouse that a distributor has for this purpose. Before the distributors, in this case Weeco Pharma, can distribute the bottles of oil to the pharmacies that have placed orders for them, Weeco Pharma must register this batch according to the applicable legislation and send this to the relevant authority. This happens as follows. The batch must be tested, and a batch-specific analysis certificate must be available, proving that the oil complies with the requirements of the German drug monograph; this is a complicated process, and the batch can only proceed once the authorities have given the green light. Just a very important detail: No distributor may order more medical cannabis than they know there are prescriptions for. They are therefore not allowed to order more cannabis medicine based on their hunches or forecasts, because they believe there will be a boom. That is why we see signs of bottlenecks across the board, because even though they could probably figure out that this boom would come, Weeco Pharma could not buy extra oil as a precaution. Now the oil has arrived at the pharmacies that ordered it. The same rule applies to pharmacies; they may not order more cannabis medicine than they can document there are prescriptions for. When the oil arrives at the pharmacy, the pharmacy must perform a laboratory test to confirm the product's identity, that the content actually matches the label. Documentation: The result of this test is entered into the pharmacy's internal logbooks. As soon as the pharmacy has completed its own internal incoming inspection and documented it, they may sell the oil immediately to patients with a valid prescription. Germany is known for having the most regulating and strict legislation for cannabis medicine. That was broadly how it works in Germany. It is also why I cannot immediately ascertain whether a batch has been released or whether the few pharmacies that have the oil in stock again have bought it internally. (Which pharmacies also need to be approved for) I hope that the above has given you a better understanding of why we are currently experiencing signs of drought in Germany right now.Denmark actually has a very strict and specific set of rules in this area. It has therefore been difficult to build a broad product portfolio, because both companies and specific products must meet Danish legal requirements before they can be included in the scheme. Perhaps one might also wonder why Astrum is not (yet) available in DK. In Denmark, the doctor must simultaneously take full responsibility for the prescription, including assessing dosage, effect, and risk of side effects themselves. This is, among other things, one of the issues that can make doctors reluctant to prescribe medical cannabis. And aren't you confusing different product categories with magistral preparation? Here, the medicine is prepared at the pharmacy according to the doctor's instructions for the specific patient. So it's a bit more extensive than "scan the barcode and dispense". In fact, a lot of cannabis comes this way - also in Germany. https://laegemiddelstyrelsen.dk/da/special/medicinsk-cannabis/ordningen-med-medicinsk-cannabis/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt